Center for Cell Death, Injury, and Regeneration, Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, SC 29425, USA.
Toxicol Appl Pharmacol. 2013 Dec 1;273(2):345-54. doi: 10.1016/j.taap.2013.09.026. Epub 2013 Oct 3.
Kidney ischemia-reperfusion (I/R) injury elicits cellular injury in the proximal tubule, and mitochondrial dysfunction is a pathological consequence of I/R. Promoting mitochondrial biogenesis (MB) as a repair mechanism after injury may offer a unique strategy to restore both mitochondrial and organ function. Rats subjected to bilateral renal pedicle ligation for 22 min were treated once daily with the SIRT1 activator SRT1720 (5mg/kg) starting 24h after reperfusion until 72h-144 h. SIRT1 expression was elevated in the renal cortex of rats after I/R+vehicle treatment (IRV), but was associated with less nuclear localization. SIRT1 expression was even further augmented and nuclear localization was restored in the kidneys of rats after I/R+SRT1720 treatment (IRS). PGC-1α was elevated at 72 h-144 h in IRV and IRS kidneys; however, SRT1720 treatment induced deacetylation of PGC-1α, a marker of activation. Mitochondrial proteins ATP synthase β, COX I, and NDUFB8, as well as mitochondrial respiration, were diminished 24h-144 h in IRV rats, but were partially or fully restored in IRS rats. Urinary kidney injury molecule-1 (KIM-1) was persistently elevated in both IRV and IRS rats; however, KIM-1 tissue expression was attenuated in IRS rats. Additionally, sustained loss of Na(+),K(+)-ATPase expression and basolateral localization and elevated vimentin in IRV rats was normalized in IRS rats, suggesting restoration of a differentiated, polarized tubule epithelium. The results suggest that SRT1720 treatment expedited recovery of mitochondrial protein expression and function by enhancing MB, which was associated with faster proximal tubule repair. Targeting MB may offer unique therapeutic strategy following ischemic injury.
肾缺血再灌注(I/R)损伤会引起近端小管的细胞损伤,线粒体功能障碍是 I/R 的病理后果。在损伤后促进线粒体生物发生(MB)作为一种修复机制可能提供一种独特的策略来恢复线粒体和器官功能。将大鼠的双侧肾蒂结扎 22 分钟,再灌注后 24 小时开始每日用 SIRT1 激活剂 SRT1720(5mg/kg)处理一次,持续 72h-144 h。I/R+载体处理(IRV)后大鼠肾皮质 SIRT1 表达升高,但核定位较少。I/R+SRT1720 处理(IRS)后大鼠肾脏 SIRT1 表达进一步增加,核定位恢复。PGC-1α 在 IRV 和 IRS 肾脏中于 72 h-144 h 升高;然而,SRT1720 处理诱导 PGC-1α去乙酰化,这是激活的标志物。ATP 合酶β、COX I 和 NDUFB8 等线粒体蛋白以及线粒体呼吸在 IRV 大鼠中于 24 h-144 h 减少,但在 IRS 大鼠中部分或完全恢复。IRV 和 IRS 大鼠的尿肾损伤分子-1(KIM-1)持续升高;然而,IRS 大鼠的 KIM-1 组织表达减少。此外,IRV 大鼠中持续丢失的 Na(+),K(+)-ATPase 表达和基底外侧定位以及升高的波形蛋白在 IRS 大鼠中恢复正常,表明分化的、极化的小管上皮细胞得到恢复。结果表明,SRT1720 处理通过增强 MB 加速恢复线粒体蛋白表达和功能,这与近端小管修复更快有关。靶向 MB 可能为缺血性损伤后提供独特的治疗策略。